FOXA2 and asthma: Ding F et al. discovered that LPS pretreatment inhibited IL-13 stimulation of ROS generation and the activation of JAK2/STAT6 pathways, thus promoted transcription factor FOXA2, inhibited excessive mucus secretion in asthma [32].